Arindam

Chatterjee

Assistant Professor

School of Pharmacy

Bunting Hall (BUN) 206

achatterjee@ndm.edu

410-532-5042

Programs I Teach

Doctor of Pharmacy

Education

Ph.D. – Medicinal Chemistry-University of Mississippi, School of Pharmacy, University, MS, US
M.S. – Medicinal Chemistry-University of Mississippi, School of Pharmacy, University, MS, US
B.S. (Honors) – Chemistry –Calcutta University, Calcutta, India
B.Tech. – Pharmaceutical Technology-Calcutta University, Calcutta, India

Biography

Research Scientist– Pfizer, Ann Arbor, MI
Research Scientist – Eli Lilly and Company, Indianapolis, IN
NIH post-doctoral fellow – Vanderbilt University, Nashville, TN (Mentor: Dr. Craig Lindsley)
Research Assistant Professor – St. Louis University, St. Louis, MO
Senior Scientist – Washington University of St. Louis, St. Louis, MO

Research Interests

Drug discovery, computational chemistry
Neurodegeneration
Oncology
Metabolic syndrome

Dr. Chatterjee’s current research interest focuses on drug-discovery projects related to the development of modulators on Kinase, and Nuclear Hormone receptor targets. We are developing drug molecules to target diseases like Alzheimer’s Disease, Cancer, Obesity, and Type 2 Diabetes. The research involves virtual screening, core medicinal chemistry, structure-activity-relationship, analytical chemistry, and computational chemistry. We utilize these techniques to screen, design, synthesize, and characterize new molecules for the targets.

Publications and Presentations

Google Scholar, MyNCBI

Current Selected Publications:

“A synthetic ERR agonist alleviates metabolic syndrome”, J. Pharmacol. Expt. Ther.; 388(2), 232-243. (2024). DOI: 10.1124/jpet.123.001733

"Computational Methods and Tools for Sustainable and Green Approaches in Drug Discovery", in Green Approaches in Medicinal Chemistry for Sustainable Drug Design, (Second Edition) Banik B.K. Ed.; Vol 2, chapter 27, 603-616, Elsevier, ISBN 978-0-443-16164-3. (2024). DOI 10.1016/B978-0-443-16164-3.00024-8

“International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023. Pharmacol. Rev.; 75 (6), 1233-1318. (2023). DOI 10.1124/pharmrev.121.000436

“Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney”, Am. J. Pathol.; 193(12), 1969-1987, (2023). DOI: 10.1016/j.ajpath.2023.07.008

“Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915.” Eur. J. of Med. Chem., 258, 115582. DOI 10.1016/j.ejmech.2023.115582

“Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity”, ACS Chem. Biol.; 18(4), 756-771, (2023), DOI: 10.1021/acschembio.2c00720

“Preparation of substituted purines and naphthyridines as REV-ERB agonists”, WO2022093552, (2022).

“Structural basis of synthetic agonist activation of the nuclear receptor REV-ERB”, Nat. Commun.; 13, 7131 (2022), DOI: 10.1038/s41467-022-34892-4

“CRTC1/MAML2 directs a PGC-1α-IGF-1 circuit that confers vulnerability to PPARγ inhibition”, Cell Rep.; 34(8), 108768, (2021), DOI: 10.1016/j.celrep.2021.108768

“A two-hit model of alcoholic liver disease that exhibits rapid, severe fibrosis”, PLoS One; 16(3), e0249316, (2021), DOI: 10.1371/journal.pone.0249316

“LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple-negative breast cancer”, Sci. Rep.; 9(1), 19530, (2019), DOI: 10.1038/s41598-019-56038-1

“Preparation of substituted isoquinolines Lxr inverse agonists for the treatment of cancer”, WO2017223514, (2017).

“Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics”, J. Immunol.; 198, 3705-3718. (2017)DOI: 10.4049/jimmunol.1601932